Drug Discovery World
JUNE 15, 2023
ACROBiosystems, through ACRO Certify and under its Aneuro brand, has launched in vivo electrophysiology solutions for neuroscience research with Diagnostic Biochips. Together, the two companies are committed to a collaborative effort to accelerate neurological drug discovery and commercialisation.
pharmaphorum
AUGUST 10, 2020
Gilead has filed its COVID-19 drug remdesivir with the FDA, to treat patients with severe disease, under the brand name Veklury. Originally intended as a treatment for Ebola virus, Veklury is a nucleotide analogue with broad-spectrum antiviral activity both in vitro and in vivo in animal models against several emerging viruses.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MARCH 4, 2024
By effectively running bioassays and analysing results, drug developers can efficiently optimise lead compounds, predict in vivo efficacy, and gain insights into the mechanism of action. Overall, these benefits lead to cost and time savings, improved efficiency, and increased success rates in drug discovery and development endeavours.
Drug Discovery World
APRIL 10, 2023
Historically, this has been predominantly driven by generic drugs, with branded generics making up 70-80% of the retail market. It is emerging markets like India that analysts expect to spearhead the global growth of the pharmaceutical sector 1. India’s domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 2.
Drug Discovery World
AUGUST 22, 2023
In many cases, it is also challenging to apply traditional bioequivalence methods or to ensure clarity about the comparison model (in-vitro/in-vivo) needed to gain health authority approval. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. What are complex generics?
Pharma Marketing Network
DECEMBER 21, 2020
those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e.,
The Pharma Data
DECEMBER 13, 2020
The aplastic anemia investigational new drug application is currently filed with the FDA under the brand name CordIn®, which is the same investigational development candidate as omidubicel. The revised plan could support a potential commercial launch of omidubicel in the United States as early as mid-2022. About Omidubicel.
Expert insights. Personalized for you.
52 
Let's personalize your content